Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kalra, P. R
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Has abciximab's ship come in?

Results from the ADMIRAL investigators and diabetic substudy

Paul R Kalra

National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK, p.kalra{at}ic.ac.uk

The ADMIRAL (Abciximab before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term follow-up) study is a multicentre, double-blind trial in 300 patients presenting with myocardial infarction. They were randomised to treatment with abciximab or placebo, followed by stenting. Abciximab treatment in diabetic and non-diabetic patients improved outcomes at 30 days and 6 months, with these improvements being related to a higher frequency of normal coronary blood flow at 24 hours and 6 months after intervention.

Key Words: myocardial infarction • primary angioplasty • anti-platelet agent.

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 1, 30-31 (2002)
DOI: 10.1177/14746514020020011501
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?